Search

Displaying results 3371 - 3380 of 10000 in total
  1. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype … Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection.

    Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein inhibitorsProducts: DASVIR 30 (DACLATASVIR TABLETS 30 MG), DASVIR 60 (DACLATASVIR TABLETS 60 MG)
  2. Target

    Mitogen-activated protein kinase kinase kinase 10

    go.drugbank.com/bio_entities/BE0009462
    TargetHumans

    Activates the JUN N-terminal pathway

    Polypeptides: Mitogen-activated protein kinase kinase kinase 10
  3. Target

    Tumor necrosis factor ligand superfamily member 10

    go.drugbank.com/bio_entities/BE0010497
    TargetHumans

    Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the d...

    Polypeptides: Tumor necrosis factor ligand superfamily member 10
  4. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus

    Categories: Type I Interferon Receptor AntagonistProducts: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET
  5. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.

    Mixtures: INOTYOL® POMADAProducts: İHTİYOL ES HEALTH PHARMA % 10 MERHEM, 20 G, Hakay İhtiyol %10 Merhem, 20 G
  6. Drug

    Vespula vulgaris venom protein

    go.drugbank.com/drugs/DB11033
    Approved

    Vespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.

    Mixtures: Mixed Vespid Venom Protein Multidose 13.0 Ml (3900 Mcg), Hymenoptera Venom Product-mixed Vespid Venom Protein (1650 Mcg)Products: ALUTARD SQ Wespengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml), ALUTARD SQ Wespengift 100.000 SQ-E/ml Injektionssuspension (Fortsetzungsbehandlung)
  7. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_. … [A230348] Due to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated

    Synonyms: L-cis-1,2-epoxypropylphosphonic acid, (2R-cis)-(3-Methyloxiranyl)phosphonic acidProducts: FOSFOMICINA EG, Fomicyt 40 mg/ml Pulver zur Herstellung einer Infusionslösung
  8. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082] … Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching.

    Mixtures: TİNAGEN 1 MG+10 MG/1 G DERİ KREMİ, 15 G, TRODERM 10 MG/G+1 MG/G KREM ,15 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Mecobalamin

    go.drugbank.com/drugs/DB03614
    ApprovedInvestigational

    Mixtures: Medi-10, Folika-TCategories: Heterocyclic Compounds, 1-Ring, Vitamin B Complex
  10. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

    Synonyms: 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid, 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acidCategories: 4-Quinolones, Heterocyclic Compounds, 2-Ring